Please ensure Javascript is enabled for purposes of website accessibility

NextCure Delays 2 Clinical Trials Due to Coronavirus

By Eric Volkman - Apr 14, 2020 at 2:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company cited patient safety concerns and the current strains on hospitals as the reasons for the postponements.

On Monday, clinical-stage biopharmaceutical company NextCure (NXTC -2.25%) announced that it would be delaying the start of upcoming phases of clinical trials for two immuno-oncology drug candidates, NC318 and NC410.

"The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety," the company wrote in a business update. "We, like others in our industry, are working closely with our clinical partners and taking the necessary steps to adjust our protocols and timelines as required during this challenging time."

Cancer immunotherapy.

Image source: Getty Images.

NexCure said it would follow through with activities for patients in the ongoing phase 2 portion of its monotherapy trial for NC318. The combination trial of the drug candidate is being put on hiatus.

The phase 1 clinical trial for NC410 was to start in March; it, too, is being pushed back.

The biotech company emphasized that these delays are temporary, but did not offer any indications about how long they might last.

NextCure management did note in the update that they anticipate reporting initial biomarker data from the phase 1 monotherapy trial for NC318 in the middle of this year. Initial data from the phase 2 study will be delayed; the company did not provide further details.

NextCure went public last year and ended up being one of 2019's best-performing new stocks. Immuno-oncology is a field with great promise and has attracted significant investor interest, so the young company already has a relatively high profile in the biotech world.

NextCure was outpacing the general stock market on Tuesday, with its share price up more than 7% in mid-afternoon trading, compared to an almost 3% rise for the S&P 500 index. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NextCure, Inc. Stock Quote
NextCure, Inc.
NXTC
$4.77 (-2.25%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.